Reply

We appreciate the interest shown by Drs Modjtahedi and Fong in our study. However, we would like to clarify some points that they have raised regarding the nepafenac 0.3% studies and the outcomes.

Source: Ophthalmology - December 18, 2017 Category: Opthalmology Authors: Rishi P. Singh, Robert Lehmann, Joseph Martel, Kevin Jong, Ayala Pollack, Alexis Tsorbatzoglou, Giovanni Staurenghi, Guadalupe Cervantes-Coste Cervantes, Louis Alpern, Satish Modi, Liza Svoboda, Adeniyi Adewale, Glenn J. Jaffe Tags: Correspondence Source Type: research